<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18603">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02864706</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001ANO05</org_study_id>
    <nct_id>NCT02864706</nct_id>
  </id_info>
  <brief_title>SCHEDULE Follow Up Visit 5-7 yr</brief_title>
  <acronym>CRAD001ANO05</acronym>
  <official_title>5, 6 or 7 Year Follow-up Control After the SCHEDULE Study (SCANDINAVIAN HEART TRANSPLANT EVEROLIMUS DE NOVO STUDY WITH EARLY CNI AVOIDANCE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is written to describe the procedures for a single 5, 6 or 7 year follow-up
      control visit of patients who participated in the 12-month SCHEDULE-study and the following
      3-year follow-up examination/visit. The aim of this 5 to 7-year follow-up visit is to
      examine the effect of long term treatment, i.e. 5, 6 or 7 years, with early initiation of
      everolimus (Certican®) and early elimination of cyclosporine (CsA), compared to standard
      immunosuppressive regimen including CsA, on renal and heart function. During the time period
      of this follow-up examinations, this visit will be performed as part of a routine annual
      visit 5, 6 or 7 years since transplantation (and inclusion in the original SCHEDULE study).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function</measure>
    <time_frame>within 5-7 years</time_frame>
    <description>Renal function as assessed by measured GFR (mGFR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression of CAV</measure>
    <time_frame>within 5-7 years</time_frame>
    <description>Progression of CAV by IVUS analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial structure and function</measure>
    <time_frame>within 5-7 years</time_frame>
    <description>Myocardial structure and function by echocardiography assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>within 5-7 years</time_frame>
    <description>Number of AE/SAE experienced sinc elast visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by SF-36</measure>
    <time_frame>within 5-7 years</time_frame>
    <description>Quality of life by SF-36 (Minnesota Living with Heart Failure Questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro Quality of Life 5D</measure>
    <time_frame>within 5-7 years</time_frame>
    <description>Euro Quality of Life 5D (EQ 5D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI) form</measure>
    <time_frame>within 5-7 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Heart Transplantation</condition>
  <arm_group>
    <arm_group_label>EVEROLIMUS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients who were included in the initial core study Schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>All patients, independent of their initial randomization in the core study, are now followed up as in one single group</description>
    <arm_group_label>EVEROLIMUS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who participated in the SCHEDULE 12-month main study, and who completed the
             3 year follow-up visit

          -  Patients who are coming for a regular annual clinic visit 5 to 7 years after
             randomization in the main study

          -  Obtaining of a separate signed patient informed consent will be required for
             participation in this follow-up examination.

        Exclusion Criteria:

          -  Patients with a retransplanted heart since the original SCHEDULE study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Gullestad, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital Rikshospitalet, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Eiskjaer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skejby Hospital, Aarhus, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Finn Gustafsson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Goran Dellgran, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Gothenburg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Goran Rådegran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Skejby Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>D-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>D-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>N-0372</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>22241</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 9, 2016</lastchanged_date>
  <firstreceived_date>June 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
